title: Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.
abstract: BACKGROUND
  The object of this study was to investigate the clinical predictive capability of peripheral myeloid dendritic cells (DCs) in Wilms' tumor 1 (WT1) vaccine therapy for patients with gynaecological cancer.
  
  
  METHODS
  Six patients with WT1/human leukocyte antigen (HLA)-A*2402-positive gynaecological cancer were included in this study. The patients received intradermal injections of a modified 9-mer WT1 peptide every week for 12 weeks. Peripheral blood samples were obtained at 0, 4, 8 and 12 weeks after the initial vaccination. Circulating DCs were detected by flow cytometry.
  
  
  RESULTS
  The frequencies of CD14(+)CD16(+)CD33(+)CD85(+) myeloid DCs were significantly higher in the therapeutically effective group than in therapeutically inert group (p<0.05).
  
  
  CONCLUSIONS
  These results suggested that myeloid DCs, which should be associated with inducing cytotoxic T-cells, provided additional prognostic information in the use of cancer peptide vaccine.
authors.affiliation: Consolidated Research Institute for Advanced Science and Medical Care, Waseda University, 513, Wasedatsurumaki-cho, Shinjuku-ku, Tokyo 162-0041, Japan. satoshi.ohno55@gmail.com
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ohno
authors.forename: Fumihide
authors.initials: F
authors.lastname: Takano
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Ohta
authors.forename: Satoru
authors.initials: S
authors.lastname: Kyo
authors.forename: Subaru
authors.initials: S
authors.lastname: Myojo
authors.forename: Satoshi
authors.initials: S
authors.lastname: Dohi
authors.forename: Haruo
authors.initials: H
authors.lastname: Sugiyama
authors.forename: Tomihisa
authors.initials: T
authors.lastname: Ohta
authors.forename: Masaki
authors.initials: M
authors.lastname: Inoue
mesh_terms: D000276:Adjuvants, Immunologic; D000328:Adult; D001772:Blood Cell Count; D019496:Cancer Vaccines / Q000276:immunology*; D003131:Combined Modality Therapy; D003713:Dendritic Cells; D005260:Female; D005434:Flow Cytometry; D005833:Genital Neoplasms, Female / Q000097:blood* / Q000188:drug therapy / Q000276:immunology / Q000601:surgery / Q000628:therapy; D015234:HLA-A Antigens / Q000008:administration & dosage / Q000276:immunology; D059871:HLA-A24 Antigen; D006801:Humans; D007115:Immunization Schedule; D007157:Immunologic Surveillance; D016130:Immunophenotyping; D016233:Immunotherapy, Active; D007271:Injections, Intradermal; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology; D016896:Treatment Outcome; D047368:Tumor Burden; D022223:Vaccines, Subunit / Q000276:immunology; D025721:WT1 Proteins / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D015234:HLA-A Antigens; C438506:HLA-A*24:02 antigen; D059871:HLA-A24 Antigen; D010446:Peptide Fragments; D022223:Vaccines, Subunit; D025721:WT1 Proteins